Jacobs JW, Figueroa Villalba CA, Booth GS, Woo JS, Stephens LD, Adkins BD. Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review. Blood Adv. 2023;7(11):2520–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brugnara C. Paroxysmal cold hemoglobinuria. Robert R, Tirnauer J, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed on January 20, 2024.

Nakahara E, Yagasaki H, Kanno H. Paroxysmal cold hemoglobinuria in japan: a literature review. Jpn J Transfus Cell Ther. 2021;67(6):541–8.

Article  Google Scholar 

Berentsen S, Sundic T. Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. BioMed Res Int. 2015;2015: 363278.

Article  PubMed  PubMed Central  Google Scholar 

Ueda Y. Advances in understanding the pathogenesis and treatment of autoimmune hemolytic anemia. Rinsho Ketsueki. 2022;63:1014–25 ((In Japanese)).

PubMed  Google Scholar 

Röth A, Barcellini W, D’Sa S, Miyakawa Y, Broome CM, Michel M, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021;384(14):1323–34.

Article  PubMed  Google Scholar 

Luo S, Hu D, Wang M, Zipfel PF, Hu Y. Complement in hemolysis- and thrombosis- related diseases. Front Immunol. 2020;11:1212.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Röth A, Bommer M, Hüttmann A, Herich-Terhürne D, Kuklik N, Rekowski J, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018;2:2543–9.

Article  PubMed  PubMed Central  Google Scholar 

Lau-Braunhut SA, Stone H, Collins G, Berentsen S, Braun BS, Zinter MS. Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Adv. 2019;3:3575–8.

Article  PubMed  PubMed Central  Google Scholar 

Al-kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Batiha GE-S. Hemolytic anemia in COVID-19. Ann Hematol. 2022;101:1887–1895.

Russotto Y, Micali C, Marino A, Ceccarelli M, Caci G, Rullo EV, et al. COVID-19 infection and severe autoimmune haemolytic anaemia: A case report and review of the literature. World Acad Sci J. 2023;5:1–11.

Article  Google Scholar 

Pelletier J, Ward C, Borloz M, Ickes A, Guelich S, Edwards E. A case of childhood severe paroxysmal cold hemoglobinuria with acute renal failure successfully treated with plasma exchange and eculizumab. Case Rep Pediatr. 2022;2022:1–5.

Article  Google Scholar 

Gregory GP, Opat S, Quach H, Shortt J, Tran H. Failure of eculizumab to correct paroxysmal cold hemoglobinuria. Ann Hematol. 2011;90:989–90.

Article  PubMed  Google Scholar 

Röth A, Berentsen S, Barcellini W, D’Sa S, Jilma B, Michel M, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022;140:980–91.

Article  PubMed  PubMed Central  Google Scholar 

Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370:632–9.

Article  CAS  PubMed  Google Scholar 

Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125:775–783.